Pankit Vachhani, MD
Hematology & Oncology · Birmingham, ALNPI 1982968764
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Incyte Corporation at 35.8% of the total. 2025 is the largest year on record at $168,654, 3.7 times the $45,784 reported in 2019. Among hematology & oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 642 payments — averaging $849.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$195K
- Blueprint Medicines Corporation$93K
- GSK$46K
- AbbVie$38K
- Karyopharm Therapeutics Inc.$27K
- Merck$24K
- plus $122K from 30 others
Across 1,568 payments — averaging $4695.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.6M
- Takeda Pharmaceuticals U.S.A., Inc.$1.3M
- Incyte Corporation$1.1M
- Blueprint Medicines Corporation$542K
- AbbVie$406K
- Karyopharm Therapeutics Inc.$396K
- plus $2M from 16 others
What the payments were for
- Consulting fees$254,58847%
- Speaking & faculty fees$225,64941%
- Travel & lodging$48,5239%
- Food & beverage$16,6583%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 221 | $195,447 |
| Blueprint Medicines Corporation | 107 | $93,327 |
| GSK | 21 | $45,755 |
| AbbVie | 72 | $38,456 |
| Karyopharm Therapeutics Inc. | 27 | $26,655 |
| Merck | 21 | $23,646 |
| Pharmaessentia USA Corporation | 9 | $18,111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $17,984 |
| Jazz Pharmaceuticals Inc. | 18 | $9,613 |
| Servier Pharmaceuticals LLC | 15 | $9,509 |
| Agios Pharmaceuticals, Inc. | 20 | $9,415 |
| CTI Biopharma Corp. | 11 | $8,692 |
| Syndax Pharmaceuticals, Inc. | 14 | $8,625 |
| Genentech, Inc. | 7 | $6,568 |
| Sobi, Inc | 14 | $6,335 |
| Stemline Therapeutics Inc. | 12 | $4,078 |
| Astellas Pharma US Inc | 8 | $4,066 |
| Pfizer | 2 | $3,526 |
| Gilead(2 entities) | 6 | $3,375 |
| Morphosys, US Inc. | 3 | $2,845 |
| Daiichi Sankyo Inc. | 1 | $2,096 |
| Novartis | 2 | $2,011 |
| Amgen | 3 | $1,978 |
| Genentech USA, Inc. | 1 | $1,650 |
| Beigene USA, Inc. | 1 | $525 |
| Sumitomo Pharma America, Inc. | 3 | $262 |
| Bristol Myers Squibb | 4 | $259 |
| AstraZeneca | 1 | $125 |
| Rigel Pharmaceuticals, Inc. | 1 | $104 |
| Sanofi | 1 | $99 |
| Geron Corporation | 1 | $80 |
| Ipsen Biopharmaceuticals, Inc | 1 | $71 |
| Aadi Bioscience, Inc. | 1 | $50 |
| Astellas Pharma Global Development | 1 | $49 |
| Lilly USA, LLC | 1 | $40 |
| Exelixis Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$545,463 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 165 | $2,758,600 |
| AyvakitAvapritinib | 38 | $1,402,706 |
| VonjoPacritinib Citrate | 41 | $981,207 |
| OjjaaraMomelotinib Dihydrochloride | 31 | $834,404 |
| SprycelDasatinib | 84 | $748,885 |
| BosulifBosutinib | 39 | $400,096 |
| TibsovoIvosidenib | 12 | $355,679 |
| TasignaNilotinib Hcl | 17 | $317,690 |
| PromactaEltrombopag Olamine | 14 | $191,672 |
| Dasatinib | 21 | $150,998 |
| InqoviDecitabine/Cedazuridine | 17 | $131,835 |
| Imatinib Mesylate | 29 | $64,938 |
| VenclextaVenetoclax | 38 | $50,987 |
| Posaconazole | 17 | $39,770 |
| EliquisApixaban | 36 | $22,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $195,447 | $2,758,600165 claims |
| Blueprint Medicines CorporationAyvakit | $93,327 | $1,402,70638 claims |
| GSKOjjaara | $45,755 | $834,40431 claims |
| NovartisTasigna, Promacta | $2,011 | $509,36231 claims |
| PfizerBosulif, Eliquis | $3,526 | $422,16475 claims |
| Servier Pharmaceuticals LLCTibsovo | $9,509 | $355,67912 claims |
| AbbVieVenclexta | $38,456 | $50,98738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
- Christos VaklavasBirmingham$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.